Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Heslop

Interventional Cardiology Boise, ID Medical Doctor

NPI 1144544644 CMS profile 1399228

6140 W Curtsian, Ste 200, Boise, ID 83704

Open in the dashboard

General payments

$17,199

275 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$33,623 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Jeffrey Heslop of Boise, ID is reported in the CMS Open Payments database as having received $17,199 across 275 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $33,623 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 72nd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,025 45
2024 General $9,107 73
2023 General $1,136 50
2022 General $1,685 49
2021 General $1,553 27
2020 General $598 14
2019 General $2,094 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Heslop
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Jeffrey Heslop were reported at $1,025. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Jeffrey Heslop Interventional Cardiology median Middle half National median
2019 $2,094 $1,097 $329–$3,048 $163
2020 $598 $473 $161–$1,480 $114
2021 $1,553 $677 $233–$1,827 $132
2022 $1,685 $978 $333–$2,724 $149
2023 $1,136 $1,136 $382–$2,986 $160
2024 $9,107 $1,181 $395–$3,326 $164
2025 $1,025 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $9,495 64 payments
  2. Boston Scientific Corporation $4,854 149 payments
  3. Abbott Laboratories $2,060 26 payments
  4. Abiomed $270 6 payments
  5. Novartis Pharmaceuticals Corporation $120 8 payments
  6. Amgen Inc. $101 5 payments
  7. Pfizer Inc. $59 4 payments
  8. Shockwave Medical, Inc $59 4 payments
  9. Penumbra, Inc. $50 1 payment
  10. LivaNova USA, Inc. $23 1 payment
  11. Other $107 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,643 252 payments
  2. Travel and Lodging $4,385 19 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,000 1 payment
  4. Grant $145 1 payment
  5. Education $26 2 payments
Products named General payments · program years 2019–2025
  1. WATCHMAN Structural Heart $1,938 14 payments
  2. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $1,872 16 payments
  3. WATCHMAN Access System $817 51 payments
  4. WATCHMAN FLX $660 23 payments
  5. VersaCross Steerable Access Solution $513 29 payments
  6. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $428 6 payments
  7. SAPIEN 3 Ultra RESILIA $409 10 payments
  8. EDWARDS SAPIEN XT TRANSCATHETER HEART VALVE (THV) $397 6 payments
  9. WATCHMAN Pain Management $368 7 payments
  10. Edwards SAPIEN XT Transcatheter Heart Valve $314 5 payments
  11. Other $2,577 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

159

Median for Interventional Cardiology: 2,236

Drug cost

$17,235

Median for Interventional Cardiology: $380,412

Branded share of claims

6.9%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 11 $15,848
Metoprolol Succinate Generic 33 $272
Ezetimibe Generic 14 $241
Atorvastatin Calcium Generic 21 $213
Potassium Chloride Generic 13 $185
Spironolactone Generic 21 $174
Furosemide Generic 18 $146
Losartan Potassium Generic 13 $93
Warfarin Sodium Generic 15 $65

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$100,711

Medicare's payments for the services billed

Medicare patients

567

Average age 78

Services billed

1,322

265 women, 302 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 57%
Arthritis 51%
Atrial fibrillation 50%
Heart failure 49%
Chronic kidney disease 38%
Diabetes 37%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $6
$6 11 —
NURTEC ODT
  • PFIZER INC. $6
$6 — —
PAXLOVID
  • PFIZER INC. $6
$6 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

275 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record